bioAffinity Technologies (NASDAQ: BIAFW) details new CyPath Lung case study

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. filed a current report to share a corporate update. On September 9, 2025, the company issued a press release announcing the release of a new case study involving its CyPath® Lung test. The case study describes how CyPath® Lung identified cancer in a patient who had an incidental finding of ground glass nodules. The press release is included with the report as an exhibit, making the information part of the company’s official disclosures.

false 0001712762 0001712762 2025-09-09 2025-09-09 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2025-09-09 2025-09-09 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2025-09-09 2025-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2025

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41463		46-5211056
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.007 per share		BIAF		The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase Common Stock		BIAFW		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 9, 2025, bioAffinity Technologies, Inc., a Delaware corporation, (the “Company”) issued a press release announcing the release of a new case study in which CyPath® Lung identified cancer in a patient with an incidental finding of ground glass nodules.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release issued by bioAffinity Technologies, Inc., dated September 9, 2025
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 9, 2025	BIOAFFINITY TECHNOLOGIES, INC.
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

FAQ

What did bioAffinity Technologies (BIAFW) disclose in this 8-K filing?

The company disclosed that it issued a press release announcing a new case study in which its CyPath® Lung test identified cancer in a patient with an incidental finding of ground glass nodules.

What is the subject of the new CyPathae Lung case study mentioned by bioAffinity Technologies?

The case study focuses on a patient with an incidental finding of ground glass nodules and explains how the CyPathae Lung test identified cancer in that patient.

When did bioAffinity Technologies release the CyPathae Lung case study press release?

bioAffinity Technologies released the press release about the CyPathae Lung case study on September 9, 2025.

Which exhibit in the 8-K contains the CyPathae Lung case study press release for bioAffinity Technologies (BIAFW)?

The press release is included as Exhibit 99.1, titled "Press Release issued by bioAffinity Technologies, Inc., dated September 9, 2025."

Does this 8-K from bioAffinity Technologies include financial results or earnings data?

No, this report is filed under Other Events and centers on a press release about a CyPathae Lung case study rather than financial or earnings information.

Who signed the 8-K report for bioAffinity Technologies related to the CyPathae Lung case study?

The report was signed on behalf of bioAffinity Technologies, Inc. by Maria Zannes, the company27s President and Chief Executive Officer.